Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01436968 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Candel Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 711
- Enrollment target
- 20
- Study locations
NCT01436968: Active Phase 3 study of Prostate Cancer, sponsored by Candel Therapeutics.
NCT01436968 is a Phase 3 study of Prostate Cancer that is active but no longer recruiting, run by Candel Therapeutics. The registered enrollment target is 711 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (17% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01436968, a Phase 3 study of Prostate Cancer, is active but no longer recruiting, sponsored by Candel Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 711 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. ProstAtak has shown synergy with radiation without added toxicity and lower than expected recurrence rates in previous clinical trials. The hypothesis is that ProstAtak can lead to improvement in the clinical outcome for patients with prostate cancer. Participants will be randomized to the ProstAtak or control arm at a 2:1 ratio. Both arms receive standard external beam radiation therapy. Short-term androgen deprivation therapy may be given but is not required.
Conditions Studied
Interventions
- BIOLOGICAL Aglatimagene besadenovec + valacyclovir
- BIOLOGICAL Placebo + valacyclovir
Study Locations (20)
Arizona
- Arizona Center for Cancer Care - Gilbert - Gilbert
- Arizona Urology Specialists - Glendale
- Arizona Oncology Services Foundation - Multiple Locations
- Arizona Center for Cancer Care - Peoria - Peoria
- Arizona Center for Cancer Care - Deer Valley - Phoenix
- Arizona Center for Cancer Care - Osborne - Scottsdale
- Arizona Center for Cancer Care - Shea - Scottsdale
- Arizona Center for Cancer Care - Surprise - Surprise
- Southern Arizona VA Health Care System - Tucson
Florida
- 21st Century Oncology - Fort Lauderdale
- 21st Century Oncology - Lakewood Rch
- 21st Century Oncology - Naples
- 21st Century Oncology - Plantation
- Clinical Research Center of Florida - Pompano Beach
Colorado
- Valley View Hospital - Glenwood Springs
- Colorado Clinical Research - Lakewood
- Advanced Urology - Parker
California
- VA Northern California Health Care System - Mather
- Precision Radiation Oncology - Tustin
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 711 participants |
| Start Date | 2011-09 |
| Est. Completion | 2030-12 |
| Phase | Phase 3 |
What the registry record for NCT01436968 still lists
NCT01436968 is an interventional study that assigns participants to a tested intervention. The registered 711 participants enrollment target is mid-sized for trials with a published cap, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (17% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Aglatimagene besadenovec + valacyclovir is the first listed.
NCT01436968 names 20 study sites across 5 states, led by Arizona, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT01436968 about?
NCT01436968 is a clinical study titled "Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer". The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimul...
What is the current status of trial NCT01436968?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 711 participants. The study started on 2011-09. Estimated completion is 2030-12.
What conditions does trial NCT01436968 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01436968?
The interventions under investigation include: Aglatimagene besadenovec + valacyclovir (BIOLOGICAL), Placebo + valacyclovir (BIOLOGICAL).
Who is sponsoring clinical trial NCT01436968?
This trial is sponsored by Candel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01436968 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01436968's enrollment target sits among peer trials
711 87th of 735 higher than 649 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
- NCT05208762 · 714 participants · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia